Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure

Congestive heart failure (CHF) is a serious disease with a poor prognosis. Diabetes is an independent risk factor for CHF, probably in part due to disturbances in myocardial metabolism. Glucagon-like pep-tide-1 (GLP-1) causes glucose-dependent secretion of insulin, improving glycaemic control. In turn, this may improve myocardial metabolism and myocardial function. The aim of the present study was to assess the feasibility and safety of three days' infusion of recombinant GLP-1 in an open observational study in six patients with type 2 diabetes and CHF. The study included assessment of myocardial function. There were no major complications of the infusion, and all patients completed the study protocol. Some improvement was observed in glycaemic state, and there was an insignificant trend towards improved myocardial function. It is concluded that GLP-1 deserves further evaluation in such patients.

[1]  J. Holst,et al.  Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7–36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships , 1995, Diabetologia.

[2]  G. Paolisso,et al.  Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. , 1997, Diabetes & metabolism.

[3]  J. Levy,et al.  Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM , 1997, Diabetologia.

[4]  M. Byrne,et al.  Human Studies with Glucagon‐like‐peptide‐1: Potential of the Gut Hormone for Clinical Use , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[5]  H. Taegtmeyer.  Energy metabolism of the heart: from basic concepts to clinical applications. , 1994, Current problems in cardiology.

[6]  A. Momose,et al.  Left ventricular filling abnormalities in non-insulin-dependent diabetes mellitus and improvement by a short-term glycemic control. , 1992, The American journal of cardiology.

[7]  B. Rodrigues,et al.  The diabetic heart: metabolic causes for the development of a cardiomyopathy. , 1992, Cardiovascular research.

[8]  J. Holst,et al.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. , 1992, The New England journal of medicine.

[9]  J. G. Miller,et al.  Abnormal myocardial acoustic properties in diabetic patients and their correlation with the severity of disease. , 1992, Journal of the American College of Cardiology.

[10]  A. Jaffe,et al.  The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. , 1989, Journal of the American College of Cardiology.

[11]  R. Danielsen,et al.  Factors contributing to left ventricular diastolic dysfunction in long-term type I diabetic subjects. , 2009, Acta medica Scandinavica.

[12]  J. Nordrehaug,et al.  Subclinical left ventricular abnormalities in young subjects with long-term type 1 diabetes mellitus detected by digitized M-mode echocardiography. , 1987, The American journal of cardiology.

[13]  R. Hartung.  Dose—Response Relationships , 1987 .

[14]  E. Sonnenblick,et al.  Clinical and morphological features of human hypertensive-diabetic cardiomyopathy. , 1980, American heart journal.

[15]  E. Newsholme,et al.  The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. , 1963, Lancet.